EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Market data and deal flow

What should a 20–60-prescriber provider do before signing?

Dose Diligence research deskSection 11 · Page 9 of 11Last updated 17 Nov 2026

The following is the desk’s recommended decision sequence, not a claim that every supplier offers these protections.

DecisionEvidence to assembleCommercial consequence
Establish route eligibilityProduct, presentation, dispensing entity, destination states and applicable legal assessmentExclude unresolved routes from the approved commercial shortlist
Identify controllable spendingRedacted invoices, payment flows and current contractsSeparate patient savings from clinic margin improvements
Obtain matched quotationsDose-mix assumptions supplied by clinical leadership; days supplied; all service charges; price-validity datePrevent starter prices or omitted fees from determining the winner
Test continuityCapacity evidence, exception reporting, escalation ownership and a transfer planPrefer verifiable service obligations over unsupported availability claims
Reconcile the 2027 boundaryApplicable offer expirations and list-price changesAvoid carrying November terms into the next budget without confirmation
Limit stranded commitmentsCancellation, clinical-stop, regulatory-change and patient-transition provisionsMake commitment exposure visible before approval

Recommended negotiating position: seek transparency on fees, fulfillment performance, data access and exit arrangements before trading flexibility for a medicine-price headline. Keep clinical selection independent of the financial model.

Explore the table row by row

A working view of the research

Establish route eligibility

Evidence to assemble
Product, presentation, dispensing entity, destination states and applicable legal assessment
Commercial consequence
Exclude unresolved routes from the approved commercial shortlist

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →